AstraZeneca Says Datopotamab Deruxtecan Showed Numerical Overall Survival Benefit Over Docetaxel In TROPION-Lung01 Trial, But Did Not Reach Statistical Significance; No OS Improvement Observed
AstraZeneca Says Datopotamab Deruxtecan Showed Numerical Overall Survival Benefit Over Docetaxel In TROPION-Lung01 Trial, But Did Not Reach Statistical Significance; No OS Improvement Observed
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.